Boris hails TraceLink's continued investment in Uxbridge
Foreign secretary Boris Johnson officially opened TraceLink’s new European headquarters in Uxbridge last week.
The new headquarters form part of a £55m investment into the pharmaceutical company’s overall global operations this year and follows an impressive 656% growth in European sales bookings for Q1.
Speaking at the launch, Johnson said: "I am delighted to join TraceLink to celebrate its continued success and decision to add further investment and jobs into the UK.
"In 2015 the UK life sciences sector contributed £30.4bn in UK GDP, supported 482,000 jobs and contributed £8.6bn in taxes.
“TraceLink's decision to create substantial job growth and invest in its European headquarters adds yet further strength to the importance of the life sciences sector to the UK economy and is a real boost for the local communities.
“With an honourable mission to help the life sciences industry protect the global medicine supply, I am proud to have companies like TraceLink right here in Uxbridge to continue pushing the UK to the forefront of the global life sciences sector.
"The government's drive to improve UK healthcare outcomes can only be helped by the ongoing success of the UK life sciences sector and companies like TraceLink continuing to innovate in order to tackle global healthcare challenges.”
The new headquarters will enable TraceLink, a life sciences technology firm which has its US headquarters in Massachusetts, to create roles for 55 new employees in Europe across sales, services, marketing and administration during 2017.
TraceLink also plans to expand its European team by more than 80% in the next 12 months as demand for its cloud network solution increases within the European pharmaceutical sector.
“Expanding and investing in our presence in Europe is a natural response to the demand we’ve seen from companies for our proven, scalable network solution to meet their serialisation needs and comply with EU FMD,” said Shabbir Dahod, president and CEO of TraceLink.
“We are deeply committed to continuing our investment into Europe and furthering our mission to enabling innovation in the global life sciences sector and protecting patients.”
Published: 27 September 2017